AGIO | Agios Pharmaceuticals, Inc.

Index	-	P/E	-	EPS (ttm)	-3.97	Insider Own	1.35%	Shs Outstand	55.27M	Perf Week	5.92%
Market Cap	1.47B	Forward P/E	-	EPS next Y	-5.50	Insider Trans	-15.67%	Shs Float	54.23M	Perf Month	5.01%
Income	-218.00M	PEG	-	EPS next Q	-1.56	Inst Own	109.02%	Short Float / Ratio	10.68% / 12.01	Perf Quarter	13.84%
Sales	19.00M	P/S	77.44	EPS this Y	28.30%	Inst Trans	-3.05%	Short Interest	5.79M	Perf Half Y	-14.91%
Book/sh	18.76	P/B	1.43	EPS next Y	11.30%	ROA	-18.10%	Target Price	37.40	Perf Year	36.28%
Cash/sh	13.47	P/C	1.99	EPS next 5Y	39.00%	ROE	-20.20%	52W Range	16.75 - 34.76	Perf YTD	-4.49%
Dividend	-	P/FCF	-	EPS past 5Y	8.90%	ROI	-22.80%	52W High	-22.84%	Beta	0.94
Dividend %	-	Quick Ratio	17.30	Sales past 5Y	-19.80%	Gross Margin	89.90%	52W Low	60.12%	ATR	1.00
Employees	389	Current Ratio	17.50	Sales Q/Q	600.00%	Oper. Margin	-	RSI (14)	63.41	Volatility	3.98% 3.56%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	15.60%	Profit Margin	-	Rel Volume	0.78	Prev Close	26.06
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 BMO	Payout	-	Avg Volume	482.26K	Price	26.82
Recom	2.20	SMA20	3.67%	SMA50	12.31%	SMA200	-0.61%	Volume	376,827	Change	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight	$64
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy	$55
May-23-19	Resumed	Goldman	Neutral	$55
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$80
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy	$117
Apr-11-18	Reiterated	Credit Suisse	Outperform	$80 → $95
Feb-15-18	Reiterated	SunTrust	Buy	$80 → $101

Show Previous Ratings

Jun-05-23 07:00AM	Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023 (GlobeNewswire)
May-30-23 09:45AM	Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
May-25-23 09:55AM	Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect? (Zacks)
07:00AM	Agios Appoints Catherine Owen to Board of Directors (GlobeNewswire)
May-11-23 10:00AM	Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress (GlobeNewswire)
09:55AM	Loading…
May-09-23 09:55AM	Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know (Zacks)
May-08-23 07:55AM	An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 48% Undervalued (Simply Wall St.)
May-05-23 10:50AM	Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
May-04-23 11:23PM	Q1 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +7.65%
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Agios Reports Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-25-23 07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023 (GlobeNewswire)
Apr-19-23 07:00AM	Agios Appoints Jeffrey Capello to Board of Directors (GlobeNewswire)
Apr-13-23 07:00AM	Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire) +5.29%
Apr-12-23 08:00AM	Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero (PR Newswire)
01:19PM	Loading…
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Apr-03-23 07:00AM	Agios Publishes 2023 Environmental, Social and Governance (ESG) Report (GlobeNewswire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 09:10AM	We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely (Simply Wall St.)
Mar-05-23 05:20AM	TipRanks Perfect 10 List: These 2 Healthcare Stocks Look Compelling at Current Levels (TipRanks)
Mar-02-23 08:26AM	Agios to Participate in March Investor Conferences (GlobeNewswire)
Feb-28-23 07:00AM	Agios Launches Red Cell Revolution in Recognition of Rare Disease Day (GlobeNewswire)
Feb-24-23 12:00PM	Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
11:49AM	Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss (Zacks)
Feb-23-23 08:45AM	Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates (Zacks)
08:38AM	Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:00AM	Agios Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-09-23 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-23 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023 (GlobeNewswire)
Jan-15-23 08:56AM	Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years ago (Simply Wall St.)
08:00PM	Loading…
Jan-08-23 08:00PM	Agios Unveils 2023-2026 Value-driving Catalysts Enabling Companys Vision to Transform Patient Outcomes in Rare Diseases (GlobeNewswire)
Jan-03-23 05:57PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (GlobeNewswire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-21-22 08:00AM	Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 (GlobeNewswire)
Dec-11-22 07:00PM	Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-10-22 06:30PM	Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent - and -Thalassemia at 64th ASH Annual Meeting and Exposition (GlobeNewswire)
Dec-06-22 07:00AM	Agios Appoints Tsveta Milanova as Chief Commercial Officer (GlobeNewswire)
Nov-30-22 08:00AM	Agios to Participate in December Investor Conference (GlobeNewswire)
Nov-17-22 05:52AM	The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup (American City Business Journals) +5.38%
Nov-11-22 11:03AM	Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients (Benzinga)
Nov-10-22 04:01PM	PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients (GlobeNewswire) +9.15%
Nov-09-22 05:36AM	Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 34%? (Simply Wall St.)
Nov-04-22 12:20PM	Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-03-22 09:00AM	Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition (GlobeNewswire) -5.25%
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Edited Transcript of AGIO.OQ earnings conference call or presentation 3-Nov-22 12:00pm GMT (Thomson Reuters StreetEvents)
07:00AM	Agios Reports Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-27-22 04:01PM	Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty (GlobeNewswire)
Oct-20-22 07:00AM	Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
Oct-02-22 09:44AM	We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-26-22 07:13PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
Sep-19-22 07:00AM	Agios Appoints Cecilia Jones as Chief Financial Officer (GlobeNewswire) +5.16%
Sep-16-22 06:41AM	Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients (GlobeNewswire) -9.51%
Sep-06-22 08:05AM	A Technical Strategy to 'Buy' Agios Pharmaceuticals (TheStreet.com)
Sep-02-22 04:02PM	Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating (Investor's Business Daily)
Aug-24-22 07:00AM	Agios to Participate in September Investor Conferences (GlobeNewswire) +6.42%
Aug-18-22 06:35PM	Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency (GlobeNewswire)
Aug-15-22 08:00AM	Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors (GlobeNewswire)
Aug-11-22 06:35PM	Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent - and -Thalassemia (GlobeNewswire) -7.90%
10:01AM	ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox (GlobeNewswire)
Aug-08-22 06:36PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer (GlobeNewswire)
08:41AM	Even after rising 38% this past week, Agios Pharmaceuticals (NASDAQ:AGIO) shareholders are still down 49% over the past five years (Simply Wall St.)
Aug-05-22 12:20PM	Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat (Zacks)
Aug-04-22 08:45AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.67%
07:00AM	Agios Reports Business Highlights and Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-14-22 07:00AM	Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-12-22 04:01PM	Former Alexion executive to take helm at Agios Pharmaceuticals (American City Business Journals)
04:01PM	Agios Appoints Brian Goff as Chief Executive Officer (GlobeNewswire)
Jun-13-22 06:30AM	CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease (GlobeNewswire) -6.11%
Jun-10-22 10:30AM	Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress (GlobeNewswire) -5.61%
Jun-02-22 05:39PM	Top Small-Cap Stocks for June 2022 (Investopedia)
May-17-22 12:13PM	Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff (Benzinga)
May-16-22 04:15PM	Agios to lay off 50 as it sets its sights on later-stage drugs (American City Business Journals)
04:15PM	Agios Announces Evolution of Research Organization (GlobeNewswire)
May-12-22 10:00AM	Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress (GlobeNewswire)
May-10-22 07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022 (GlobeNewswire) +6.71%
May-07-22 09:02AM	Does Agios Pharmaceuticals (NASDAQ:AGIO) Have A Healthy Balance Sheet? (Simply Wall St.)
May-05-22 08:15AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Agios Reports Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-21-22 07:00AM	Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022 (GlobeNewswire) -5.36%
Apr-14-22 08:34AM	Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency (GlobeNewswire) -5.36%
Mar-01-22 08:35AM	New Strong Sell Stocks for March 1st (Zacks)
Feb-28-22 07:00AM	Agios to Participate in March Investor Conferences (GlobeNewswire)
Feb-24-22 05:49PM	Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil (Zacks) +5.74%
12:03PM	The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics (Zacks)
08:55AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Agios Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-23-22 12:57PM	Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More (Zacks)
Feb-18-22 10:29AM	Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat (Zacks)
05:41AM	FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder (Benzinga)
Feb-17-22 03:41PM	Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency (GlobeNewswire) -5.18%
03:03PM	Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline (Zacks)
Feb-10-22 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022 (GlobeNewswire)
Feb-08-22 01:38PM	S&co Inc Buys Royalty Pharma PLC, Edwards Lifesciences Corp, Procter & Gamble Co, Sells ... (GuruFocus.com)
Jan-18-22 02:57PM	Top Biotech Stocks for Q1 2022 (Investopedia) -6.04%
Jan-10-22 01:38PM	Seelaus Asset Management LLC Buys Merck Inc, Eagle Materials Inc, Coinbase Global Inc, Sells ... (GuruFocus.com)
07:00AM	Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Companys Strategic Vision in Genetically Defined Diseases (GlobeNewswire)
Dec-22-21 07:00AM	Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 (GlobeNewswire)
Dec-21-21 04:27AM	Some Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Estimates (Simply Wall St.)
Dec-17-21 11:38PM	Goldman Sachs Variable Insurance Trust Growth Opportunities Fund Buys Novavax Inc, Ryan ... (GuruFocus.com) +8.18%

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FOUSE JACQUALYN A	Director	Apr 08	Option Exercise	0.00	15,933	0	98,515	Apr 12 04:17 PM
Schenkein David P	Director	Apr 03	Option Exercise	9.05	16,363	148,085	134,242	Apr 05 04:03 PM
Schenkein David P	Director	Apr 03	Sale	22.85	16,363	373,895	117,879	Apr 05 04:03 PM
Schenkein David P	Director	Mar 27	Option Exercise	9.05	20,000	181,000	137,879	Mar 29 09:30 PM
Schenkein David P	Director	Mar 27	Sale	22.15	20,000	443,000	117,879	Mar 29 09:30 PM
Schenkein David P	Director	Mar 13	Option Exercise	9.05	20,000	181,000	137,879	Mar 15 05:11 PM
Schenkein David P	Director	Mar 13	Sale	22.49	20,000	449,817	117,879	Mar 15 05:11 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 03	Sale	24.29	504	12,242	2,741	Mar 07 04:02 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01	Option Exercise	0.00	777	0	3,518	Mar 03 04:08 PM
Gheuens Sarah	Chief Medical Officer	Mar 01	Option Exercise	0.00	3,833	0	21,250	Mar 03 04:05 PM
Schenkein David P	Director	Feb 27	Option Exercise	9.05	20,000	181,000	137,879	Mar 01 04:06 PM
Schenkein David P	Director	Feb 27	Sale	25.37	20,000	507,400	117,879	Mar 01 04:06 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 16	Sale	27.21	233	6,340	2,668	Feb 21 04:05 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14	Option Exercise	0.00	360	0	3,532	Feb 16 04:04 PM
FOUSE JACQUALYN A	Director	Feb 14	Option Exercise	0.00	11,333	0	86,230	Feb 16 04:03 PM
Burns James William	Chief Legal Officer	Feb 14	Option Exercise	0.00	1,738	0	24,147	Feb 16 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14	Sale	28.59	504	14,409	2,901	Feb 16 04:04 PM
Schenkein David P	Director	Feb 13	Option Exercise	9.05	20,000	181,000	137,879	Feb 15 04:03 PM
Schenkein David P	Director	Feb 13	Sale	28.62	20,000	572,400	117,879	Feb 15 04:03 PM
Burns James William	Chief Legal Officer	Feb 10	Option Exercise	0.00	1,834	0	23,052	Feb 14 04:07 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 10	Option Exercise	0.00	777	0	3,445	Feb 14 04:06 PM
Schenkein David P	Director	Jan 30	Option Exercise	9.05	20,000	181,000	137,879	Feb 01 04:04 PM
Schenkein David P	Director	Jan 30	Sale	29.33	20,000	586,578	117,879	Feb 01 04:04 PM
Schenkein David P	Director	Jan 17	Option Exercise	9.05	20,000	181,000	137,879	Jan 19 04:03 PM
Schenkein David P	Director	Jan 17	Sale	28.85	20,000	577,093	117,879	Jan 19 04:03 PM
Burns James William	Chief Legal Officer	Dec 23	Option Exercise	0.00	8,750	0	23,815	Dec 28 04:05 PM
Gheuens Sarah	Chief Medical Officer	Dec 23	Option Exercise	0.00	9,375	0	18,388	Dec 28 04:05 PM
Gheuens Sarah	Chief Medical Officer	Dec 02	Option Exercise	0.00	833	0	9,261	Dec 06 04:14 PM
Poddar Richa	Chief Commercial Officer	Oct 15	Option Exercise	0.00	5,000	0	9,993	Oct 18 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGIO | Agios Pharmaceuticals, Inc.

Upgrade your FINVIZ experience